CAMBRIDGE, Mass.--(BUSINESS WIRE)--SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat central nervous system (CNS) diseases, today announced the company has entered into an exclusive license agreement with Washington University in St. Louis to develop and commercialize novel small molecule GABAA receptor allosteric modulators for the treatment of neuropsychiatric diseases. The technology developed at Washington University complements and strengthens SAGE’s proprietary product engine, the Positive and Negative Allosteric Modulator (PANAM) platform, and also will aid in accelerating the development of novel compounds for sedation and anesthesia during surgeries or other medical procedures.
Help employers find you! Check out all the jobs and post your resume.
